AMG 193 + Modified FOLFIRINOX

AMG 193 + Modified FOLFIRINOX is a combination investigational therapy composed of **AMG 193**, a CNS-penetrant, methylthioadenosine-cooperative PRMT5 inhibitor that selectively induces synthetic lethality in MTAP-deleted tumor cells, and a **modified FOLFIRINOX** regimen, which typically consists of chemotherapeutic agents used to treat advanced pancreatic and other solid tumors. AMG 193 targets PRMT5 and is being developed to treat cancers characterized by MTAP deletion. Modified FOLFIRINOX refers to a dosing-adjusted or component-modified version of the standard FOLFIRINOX regimen, which includes folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin, chemotherapy drugs collectively targeting rapidly dividing cancer cells. This combination is under clinical investigation for synergistic or additive efficacy, especially in advanced, difficult-to-treat solid tumors such as pancreatic cancer and other MTAP-null cancers[1][2][4][5][6].